Privia Health Group, Inc. (NASDAQ:PRVA) Position Cut by Russell Investments Group Ltd.

Russell Investments Group Ltd. trimmed its stake in Privia Health Group, Inc. (NASDAQ:PRVA – Get Rating) by 67.0% during the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 77,964 shares of the company’s stock after selling 158,330 shares during the quarter. Russell Investments Group Ltd. owned approximately 0.07% of Privia Health Group worth $1,771,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in PRVA. ProShare Advisors LLC bought a new stake in shares of Privia Health Group during the first quarter valued at about $210,000. JPMorgan Chase & Co. raised its stake in shares of Privia Health Group by 60.3% during the first quarter. JPMorgan Chase & Co. now owns 33,839 shares of the company’s stock valued at $905,000 after purchasing an additional 12,732 shares in the last quarter. US Bancorp DE raised its stake in shares of Privia Health Group by 8.8% during the first quarter. US Bancorp DE now owns 13,923 shares of the company’s stock valued at $372,000 after purchasing an additional 1,131 shares in the last quarter. MetLife Investment Management LLC raised its stake in shares of Privia Health Group by 200.9% during the first quarter. MetLife Investment Management LLC now owns 23,742 shares of the company’s stock valued at $635,000 after purchasing an additional 15,852 shares in the last quarter. Finally, Rhumbline Advisers raised its stake in shares of Privia Health Group by 124.7% during the first quarter. Rhumbline Advisers now owns 36,873 shares of the company’s stock valued at $986,000 after purchasing an additional 20,464 shares in the last quarter. 66.83% of the stock is currently owned by institutional investors.

Privia Health Group Price Performance

NASDAQ:PRVA opened at $26.22 on Tuesday. Privia Health Group, Inc. has a fifty-two week low of $20.64 and a fifty-two week high of $44.64. The stock’s 50-day moving average is $26.97 and its two-hundred day moving average is $25.88. The stock has a market cap of $3.03 billion, a PE ratio of 238.36, a price-to-earnings-growth ratio of 3.15 and a beta of 0.77.

Privia Health Group (NASDAQ:PRVA – Get Rating) last announced its quarterly earnings results on Tuesday, February 28th. The company reported $0.14 EPS for the quarter, beating the consensus estimate of ($0.03) by $0.17. The business had revenue of $364.42 million during the quarter, compared to analysts’ expectations of $337.16 million. Privia Health Group had a return on equity of 3.20% and a net margin of 1.14%. On average, equities research analysts anticipate that Privia Health Group, Inc. will post 0.23 earnings per share for the current year.

Insider Transactions at Privia Health Group

In other news, COO Parth Mehrotra sold 53,560 shares of the business’s stock in a transaction that occurred on Tuesday, February 28th. The stock was sold at an average price of $28.13, for a total transaction of $1,506,642.80. Following the sale, the chief operating officer now directly owns 97,391 shares in the company, valued at $2,739,608.83. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other news, COO Parth Mehrotra sold 53,560 shares of the stock in a transaction on Tuesday, February 28th. The stock was sold at an average price of $28.13, for a total transaction of $1,506,642.80. Following the sale, the chief operating officer now owns 97,391 shares in the company, valued at $2,739,608.83. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director William M. Sullivan sold 18,153 shares of the company’s stock in a transaction on Friday, May 12th. The shares were sold at an average price of $26.54, for a total value of $481,780.62. Following the transaction, the director now directly owns 5,673,861 shares in the company, valued at approximately $150,584,270.94. The disclosure for this sale can be found here. Insiders sold a total of 25,371,773 shares of company stock worth $551,840,171 over the last three months. 57.60% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on PRVA shares. Royal Bank of Canada started coverage on shares of Privia Health Group in a research report on Thursday, March 9th. They issued an “outperform” rating and a $36.00 price target on the stock. The Goldman Sachs Group started coverage on shares of Privia Health Group in a research report on Friday, February 3rd. They issued a “buy” rating and a $32.00 price target on the stock. SVB Securities boosted their price target on shares of Privia Health Group from $39.00 to $40.00 in a research report on Friday, May 5th. Credit Suisse Group reiterated an “outperform” rating and issued a $41.00 price target on shares of Privia Health Group in a research report on Tuesday, March 7th. Finally, Stephens started coverage on shares of Privia Health Group in a research report on Tuesday, April 11th. They issued an “overweight” rating and a $33.00 price target on the stock. Thirteen research analysts have rated the stock with a buy rating, According to MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $39.19.

Privia Health Group Company Profile

(Get Rating)

Privia Health Group, Inc operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings.